Alpha-1 Antitrypsin Deficiency - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Representative image of a large precious metals mining operation, illustrating the Fresnillo plc share price surge as investors weigh whether the FTSE 100 miner’s 2026 guidance cut is a temporary pause in the silver and gold bull run.

Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?

Representative image of commercial shipping and naval activity in the Strait of Hormuz, as Iran reopens the key oil transit route while uncertainty over the United States naval blockade continues.

Strait of Hormuz reopens on paper, yet ships turn back as Iran and US clash over blockade terms

TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record

Representative image of a large-scale copper mining operation in Chile, reflecting investor focus on Antofagasta PLC shares, Q1 2026 production stability, and the Centinela Second Concentrator growth story.

Antofagasta (LSE: ANTO) surges 5% as Q1 output beats consensus and Centinela build holds schedule

Representative image illustrating gene-editing research as YolTech Therapeutics advances YOLT-202 into a Phase 2/3 trial, exploring a potential “one-and-done” treatment for Alpha-1 Antitrypsin Deficiency.

Read More

Pharma Industry News

Why YolTech Therapeutics believes YOLT-202 could become a “one-and-done” treatment for Alpha-1 Antitrypsin Deficiency

YolTech Therapeutics receives FDA clearance to launch a Phase 2/3 trial of YOLT-202 for Alpha-1 Antitrypsin Deficiency. Discover what this means for gene editing.

March 15, 2026

web analytics